Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
334.67M | 16.84M | 15.28M | 10.48M | 8.20M | Gross Profit |
329.58M | 11.78M | 10.81M | 5.85M | 4.95M | EBIT |
241.88M | -81.06M | -225.72M | -411.57M | -159.38M | EBITDA |
251.90M | -68.28M | -196.00M | -398.86M | -64.64M | Net Income Common Stockholders |
188.71M | -95.81M | -245.36M | -410.90M | -73.43M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
303.26M | 30.96M | 111.71M | 356.86M | 573.87M | Total Assets |
339.73M | 64.14M | 153.70M | 440.25M | 692.18M | Total Debt |
10.50M | 71.41M | 81.52M | 99.77M | 47.51M | Net Debt |
-292.75M | 40.45M | -30.18M | -257.08M | -526.36M | Total Liabilities |
107.92M | 86.08M | 100.99M | 158.25M | 88.72M | Stockholders Equity |
231.82M | -21.94M | 52.71M | 282.00M | 603.46M |
Cash Flow | Free Cash Flow | |||
249.07M | -85.66M | -282.52M | -346.52M | -179.71M | Operating Cash Flow |
249.20M | -85.53M | -281.54M | -345.04M | -174.71M | Investing Cash Flow |
-124.00K | -129.00K | 6.84M | 43.16M | 99.51M | Financing Cash Flow |
23.25M | -7.97M | -20.52M | 50.60M | 621.18M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | kr1.26B | 4.81 | 152.78% | ― | 1533.99% | ― | |
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
48 Neutral | kr917.45M | ― | -48.22% | ― | ― | 67.70% | |
48 Neutral | kr379.37M | ― | -47.73% | ― | 45.52% | 93.35% | |
47 Neutral | kr1.16B | ― | -42.24% | ― | ― | -19.44% | |
41 Neutral | kr367.75M | ― | -194.31% | ― | 1643.36% | 50.36% | |
32 Underperform | kr375.12M | ― | -205.65% | ― | ― | 24.25% |
Saniona AB held its annual shareholders’ meeting on May 28, 2025, where several key resolutions were adopted. The meeting approved the financial statements for 2024, decided against issuing dividends, and re-elected board members with new appointments in leadership roles. Additionally, the meeting authorized the board to issue new shares and adopted an employee option program, reflecting strategic moves to strengthen the company’s financial position and incentivize its workforce.
Saniona AB reported a strong start to 2025, with significant financial and operational milestones achieved in the first quarter. The company secured seed funding for its joint venture, advanced regulatory processes for tesofensine, and initiated manufacturing and toxicology studies for SAN2355. Additionally, Saniona extended its collaboration with Boehringer Ingelheim and completed a successful TO4 financing, strengthening its financial position and setting the stage for continued growth.
Saniona has appointed Johnny Stilou as Chief Financial Officer, bringing over 25 years of financial leadership experience to the company. His expertise in corporate finance and capital markets is expected to support Saniona’s financial strategy and investor relations as it advances its pipeline and seeks long-term financing solutions.